Calidi Biotherapeutics Presents Immunotherapy Data at ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics Inc. (NYSE:CLDI) presented three abstracts at the 2024 ASCO Annual Meeting, including updates on their CLD-101 program and preclinical data on their RTNova (CLD-400) and CLD-201 platforms.
June 03, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calidi Biotherapeutics presented promising data at ASCO 2024, including updates on their CLD-101 program and preclinical data on RTNova (CLD-400) and CLD-201 platforms.
The presentation of promising data at a major conference like ASCO can generate positive sentiment and investor interest, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100